[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

  • Product portfolio
  • Potentially strong market reviews
  • Competitive analytics
  • Prospect partners
  • Mergers and acquisitions project data
  • Latest trends across a particular industry area
  • Research and development strategies
  • The analysis of new customers
  • A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853
Sort by:

Cells Expressing Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 45 pages

Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and...

May 2022 115 pages

Cells Expressing Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) Drugs in Development by Therapy Areas and...

May 2022 48 pages

Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protei...

May 2022 99 pages

Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indicat...

May 2022 54 pages

Cells Expressing Nectin 4 (Ig Superfamily Receptor LNIR or Poliovirus Receptor Related Protein 4 or Nectin Cell Adhesion Molecule 4 or PVRL4 or NECTIN4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Nectin 4 (Ig Superfamily Receptor LNIR or Poliovirus Receptor Related Protein 4 or Nectin Cell Adhesion Molecule 4 or PVRL4 or NECTIN4) Drugs in Development by Therapy Areas and Indic...

May 2022 46 pages

Cells Expressing NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2D Activating NK Receptor or CD314 or NKG2D or KLRK1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2D Activating NK Receptor or CD314 or NKG2D or KLRK1) Drugs...

May 2022 52 pages

Cells Expressing Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1)...

May 2022 41 pages

Cells Expressing Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Drugs in Development...

May 2022 49 pages

Cells Expressing SLAM Family Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 Like Receptor Activating Cytotoxic Cells or Novel Ly9 or Protein 19A or CD2 Subset 1 or CS1 or SLAMF7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing SLAM Family Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 Like Receptor Activating Cytotoxic Cells or Novel Ly9 or Protein 19A or CD2 Subset 1 or CS1 or SLAMF7) Drugs in Developm...

May 2022 44 pages

Cells expressing Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells expressing Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indication...

May 2022 37 pages

Cells Expressing Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or 5T4 Oncofetal Trophoblast Glycoprotein or Wnt Activated Inhibitory Factor 1 or TPBG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or 5T4 Oncofetal Trophoblast Glycoprotein or Wnt Activated Inhibitory Factor 1 or TPBG) Drugs in Development by Therapy Areas a...

May 2022 46 pages

Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TACSTD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TA...

May 2022 55 pages

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 or BCMA or TNFRSF17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 or BCMA or TNFRSF17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 188 pages

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8) Drugs in Development by Therapy Areas and...

May 2022 62 pages

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy A...

May 2022 47 pages

Cells Expressing Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1...

May 2022 36 pages

Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80) Drugs in De...

May 2022 42 pages

Cholinesterase (Butyrylcholinesterase or Acylcholine Acylhydrolase or Choline Esterase II or Pseudocholinesterase or BCHE or EC 3.1.1.8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cholinesterase (Butyrylcholinesterase or Acylcholine Acylhydrolase or Choline Esterase II or Pseudocholinesterase or BCHE or EC 3.1.1.8) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 39 pages

Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 49 pages

CX3C Chemokine Receptor 1 (Beta Chemokine Receptor Like 1 or CMK BRL1 or Fractalkine Receptor or G Protein Coupled Receptor 13 or V28 or GPR13 or CX3CR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CX3C Chemokine Receptor 1 (Beta Chemokine Receptor Like 1 or CMK BRL1 or Fractalkine Receptor or G Protein Coupled Receptor 13 or V28 or GPR13 or CX3CR1) Drugs in Development by Therapy Areas and Indi...

May 2022 37 pages

Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or CDK11 or CDK19 or EC 2.7.11.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or...

May 2022 40 pages

Cyclin Dependent Kinase 8 (Protein Kinase K35 or Mediator Of RNA Polymerase II Transcription Subunit CDK8 or Cell Division Protein Kinase 8 or Mediator Complex Subunit CDK8 or CDK8 or EC 2.7.11.22 or EC 2.7.11.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cyclin Dependent Kinase 8 (Protein Kinase K35 or Mediator Of RNA Polymerase II Transcription Subunit CDK8 or Cell Division Protein Kinase 8 or Mediator Complex Subunit CDK8 or CDK8 or EC 2.7.11.22 or...

May 2022 41 pages

Cysteinyl Leukotriene Receptor 1 (Cysteinyl Leukotriene D4 Receptor or G Protein Coupled Receptor HG55 or HMTMF81 or CYSLTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cysteinyl Leukotriene Receptor 1 (Cysteinyl Leukotriene D4 Receptor or G Protein Coupled Receptor HG55 or HMTMF81 or CYSLTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 42 pages

Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6...

May 2022 107 pages

Diacylglycerol O Acyltransferase 2 (Diglyceride Acyltransferase 2 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT2 or EC 2.3.1.76 or EC 2.3.1.20) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Diacylglycerol O Acyltransferase 2 (Diglyceride Acyltransferase 2 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT2 or EC 2.3.1.76 or EC 2.3.1.20) Drugs in Development by Therapy Areas and Indicati...

May 2022 35 pages

Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5) Drugs in Development by Therapy Areas and Indicatio...

May 2022 74 pages

DNA (Apurinic or Apyrimidinic Site) Lyase (APEX Nuclease or APEN or Apurinic Apyrimidinic Endonuclease 1 or AP Endonuclease 1 or REF 1 or Redox Factor 1 or APEX1 or EC 4.2.99.18 or EC 3.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA (Apurinic or Apyrimidinic Site) Lyase (APEX Nuclease or APEN or Apurinic Apyrimidinic Endonuclease 1 or AP Endonuclease 1 or REF 1 or Redox Factor 1 or APEX1 or EC 4.2.99.18 or EC 3.1.) Drugs in D...

May 2022 38 pages

DNA (Cytosine 5 ) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNA Methyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

DNA (Cytosine 5 ) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNA Methyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 50 pages

E Selectin (CD62 Antigen Like Family Member E or Endothelial Leukocyte Adhesion Molecule 1 or Leukocyte Endothelial Cell Adhesion Molecule 2 or LECAM2 or CD62E or SELE) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

E Selectin (CD62 Antigen Like Family Member E or Endothelial Leukocyte Adhesion Molecule 1 or Leukocyte Endothelial Cell Adhesion Molecule 2 or LECAM2 or CD62E or SELE) Drugs in Development by Therapy...

May 2022 39 pages

E3 Ubiquitin Protein Ligase CBL B (Casitas B Lineage Lymphoma Proto Oncogene b or RING Finger Protein 56 or SH3 Binding Protein CBLB or Signal Transduction Protein CBLB or CBLB or EC 2.3.2.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

E3 Ubiquitin Protein Ligase CBL B (Casitas B Lineage Lymphoma Proto Oncogene b or RING Finger Protein 56 or SH3 Binding Protein CBLB or Signal Transduction Protein CBLB or CBLB or EC 2.3.2.27) Drugs i...

May 2022 40 pages

Ectonucleoside Triphosphate Diphosphohydrolase 1 (NTPDase 1 or Ecto ATP Diphosphohydrolase 1 or Ecto Apyrase or Lymphoid Cell Activation Antigen or CD39 or ENTPD1 or EC 3.6.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ectonucleoside Triphosphate Diphosphohydrolase 1 (NTPDase 1 or Ecto ATP Diphosphohydrolase 1 or Ecto Apyrase or Lymphoid Cell Activation Antigen or CD39 or ENTPD1 or EC 3.6.1.5) Drugs in Development b...

May 2022 45 pages

Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC 1.14.11.29) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC 1.14.11.29) Drugs in Development by Therapy Areas and Indica...

May 2022 39 pages

Endothelial PAS Domain Containing Protein 1 (Basic Helix Loop Helix PAS Protein MOP2 or Class E Basic Helix Loop Helix Protein 73 or HIF 1 Alpha Like Factor or Hypoxia Inducible Factor 2 Alpha or PAS Domain Containing Protein 2 or EPAS1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Endothelial PAS Domain Containing Protein 1 (Basic Helix Loop Helix PAS Protein MOP2 or Class E Basic Helix Loop Helix Protein 73 or HIF 1 Alpha Like Factor or Hypoxia Inducible Factor 2 Alpha or PAS...

May 2022 43 pages

Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Sta...

May 2022 259 pages

Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein Kinase CAK or CD167a or DDR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein...

May 2022 42 pages

Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 (PRKR Like Endoplasmic Reticulum Kinase or Pancreatic eIF2 Alpha Kinase or EIF2AK3 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 (PRKR Like Endoplasmic Reticulum Kinase or Pancreatic eIF2 Alpha Kinase or EIF2AK3 or EC 2.7.11.1) Drugs in Development by Therapy Areas and I...

May 2022 35 pages

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Drugs in Develop...

May 2022 99 pages

Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46) Drugs in Development by Therapy Areas...

May 2022 38 pages

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC...

May 2022 40 pages

Glycylpeptide N Tetradecanoyltransferase (Myristoyl CoA:Protein N Myristoyltransferase or Peptide N Myristoyltransferase or NMT or EC 2.3.1.97) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Glycylpeptide N Tetradecanoyltransferase (Myristoyl CoA:Protein N Myristoyltransferase or Peptide N Myristoyltransferase or NMT or EC 2.3.1.97) Drugs in Development by Therapy Areas and Indications, S...

May 2022 35 pages

Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 35 pages

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Ind...

May 2022 36 pages

Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 36 pages

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 40 pages

Integrin Alpha M (CD11 Antigen Like Family Member B or CR 3 Alpha Chain or Leukocyte Adhesion Receptor MO1 or Neutrophil Adherence Receptor or CD11b or ITGAM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Integrin Alpha M (CD11 Antigen Like Family Member B or CR 3 Alpha Chain or Leukocyte Adhesion Receptor MO1 or Neutrophil Adherence Receptor or CD11b or ITGAM) Drugs in Development by Therapy Areas and...

May 2022 35 pages

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Drugs in Development by Therapy Areas an...

May 2022 52 pages

Filters

Search

Categories

2,264
2,910
126
9
6
1
1
1
4
522
3
6

Publishers

5,853

Regions

5,853

Price

Date

Pages

Offers